Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.84+0.02 (+2.78%)
Close on Nov 18, 2026Market cap $212.06MP/E –Yield –
Lineage Cell Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Lineage Cell Therapeutics's pe ratio was 3.8× on Oct 31, 2019, against 2.8× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2019 | Oct 31, 2019 | 3.8× | −3.2 |
| 2018 | Jan 31, 2018 | 6.9× | +1.8 |
| 2017 | Dec 29, 2017 | 5.1× | −12.1 |
| 2016 | Dec 30, 2016 | 17.2× | – |
See a number that looks wrong?